Roche and Illumina have entered into a 15-year non-exclusive partnership with to broaden the adoption of distributable next-generation sequencing based testing in oncology.
Qiagen and Amgen are collaborating to develop tissue-based companion diagnostics for Amgen's investigational cancer treatment AMG 510 to identify patients with cancers that have the KRAS G12C mutation.
FDA approved Keytruda (pembrolizumab) Jan. 8 for the treatment of patients with Bacillus Calmette-Guerin-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
FDA approved Ayvakit (avapritinib) Jan. 9 for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.
FDA granted accelerated approval to the drug enfortumab vedotin to treat adult patients with advanced urothelial or bladder cancer.
FDA granted clearance to IceCure Medical Ltd.'s cryoablation technology that destroys benign and cancerous tumors by freezing them.
Health Canada has approved Calquence (acalabrutinib), an oral Bruton's tyrosine kinase inhibitor, as monotherapy or in combination with obinutuzumab in the first-line setting, and as monotherapy for relapsed/refractory (r/r) disease for the treatment of adult patients with chronic lymphocytic leukemia.
FDA approved Lynparza (olaparib) for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.
FDA approved Xtandi (enzalutamide) for patients with metastatic castration-sensitive prostate cancer
FDA granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.